Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
May 19, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of...
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
May 18, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis...
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
May 04, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023;Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for...
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
April 11, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
March 01, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
February 23, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing,with data evaluating clinical...
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
February 01, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
January 10, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
January 04, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...